| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Delta-Fly Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥801.00 |
| 52 Week High | JP¥1,825.00 |
| 52 Week Low | JP¥762.00 |
| Beta | 0.18 |
| 1 Month Change | -3.49% |
| 3 Month Change | -10.80% |
| 1 Year Change | -31.83% |
| 3 Year Change | -41.15% |
| 5 Year Change | -71.19% |
| Change since IPO | -84.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4598 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -2.1% | 3.0% | 1.8% |
| 1Y | -31.8% | -24.6% | 31.0% |
Return vs Industry: 4598 underperformed the JP Biotechs industry which returned -24.6% over the past year.
Return vs Market: 4598 underperformed the JP Market which returned 31% over the past year.
Price Volatility
| 4598 volatility | |
|---|---|
| 4598 Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4598 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4598's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 11 | n/a | www.delta-flypharma.co.jp |
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
Delta-Fly Pharma, Inc. Fundamentals Summary
| 4598 fundamental statistics | |
|---|---|
| Market cap | JP¥6.59b |
| Earnings (TTM) | -JP¥1.26b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.2x
P/E RatioIs 4598 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4598 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥1.26b |
| Earnings | -JP¥1.26b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -153.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4598 perform over the long term?
See historical performance and comparison